(RTTNews) – Novavax, Inc. (NVAX), an advanced biotechnology company, announced Wednesday that it reached an agreement with the Australian government to deliver 40 million doses of its COVID-19 candidate vaccine, NVX-CoV2373.
“This agreement with the Australian government reflects the importance of NVX-CoV2373’s ongoing clinical progression and will ensure that Australian citizens have their supply,” said Stanley C. Erck, President and CEO of Novavax. “We are pleased with the progress of our ongoing Phase 3 clinical trial in the UK and are in a hurry to provide effectiveness knowledge of nvx-coV2373, with interim knowledge in this event-based trial expected in the early first quarter of 2021. “
Delivery of NVX-CoV2373 to Australia will begin in the first part of 2021, subject to a successful final touch of Phase 3 clinical progression and approval of the vaccine through the Australian Therapeutic Products Administration (TGA).
To date, Novavax has concluded agreements to supply NVX-CoV2373 directly to the United States and the United Kingdom, Canada and now Australia, and through partnerships, to the source of Japan, South Korea and India.